nitecapone (OR 462)

09/07/1995 - "In the present study, the influence of nitecapone on isolated rat heart ischemia-reperfusion injury was investigated to elucidate its cardioprotective role. "
08/01/2000 - "In spite of this increase in antioxidative capacity nitecapone could not protect the lung against ischemia-reperfusion injury when pulmonary hemodynamics, gas exchange or plasma diene conjugates were used as measures of lung graft function."
09/07/1995 - "Role of ascorbate in protection by nitecapone against cardiac ischemia-reperfusion injury."
03/01/1993 - "Nitecapone protects the Langendorff perfused heart against ischemia-reperfusion injury."
08/01/1999 - "Nitecapone has been shown to have a protective effect against ischemia-reperfusion injury in experimental heart transplantation and in Langendorff preparations. "

01/01/1999 - "The Effect of Nitecapone, a New Antioxidant, on Myocardial Function After Aortic Cross-clamping in Experimental Heart Ischemia."
03/01/1993 - "Nitecapone partially prevented the loss of total sulfhydryl groups and vitamin E after ischemia and reperfusion. "
04/01/1999 - "Nitecapone inhibits myeloperoxidase in vitro and enhances functional performance after 8 h of ischemia in experimental heart transplantation."
03/01/1993 - "We found that when present in the perfusate 10 microM nitecapone improved the mechanical function of the heart and lowered the enzyme leakage of lactate dehydrogenase after 40 minutes of global ischemia. "

08/01/2011 - "Nitecapone reduced the symptoms of neuropathic pain after the SNL, which is in line with the earlier study. "
01/13/2012 - "In addition, the nitecapone, another well-known COMT inhibitor, is also in preclinical development but for neuropathic pain. "
08/01/2011 - "Our results suggest that nitecapone and other COMT inhibitors should be studied further in the treatment of neuropathic pain."
01/01/2010 - "In different rat models of neuropathic pain, the action of nitecapone is opposite: it is antinociceptive and antiallodynic. "
08/01/2011 - "Nitecapone reduces development and symptoms of neuropathic pain after spinal nerve ligation in rats."

10/01/1988 - "The data suggest a possible beneficial effect of OR-462 in the therapy of Parkinson's disease."
01/01/1992 - "Altogether, three patients with Parkinson's disease (PD) and three normal volunteers were examined, first without nitecapone and then with an oral dose of 100 mg of nitecapone 1 hour before the IV injection of 3 mCi of [18F]6-fluorodopa. "
01/01/1992 - "[18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462)."
10/01/1988 - "Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease."
08/01/1991 - "Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease."

02/01/2001 - "DM or nitecapone treatment did not produce significant changes in phasic or tonic descending pain regulation originating in the RVM."
09/01/2012 - "In rodent pain models, COMT inhibitors are pronociceptive, except for neuropathic pain models, where nitecapone was found to be antiallodynic. "
02/01/2001 - "Pain behavior and response properties of spinal dorsal horn neurons following experimental diabetic neuropathy in the rat: modulation by nitecapone, a COMT inhibitor with antioxidant properties."